Azitra (AZTR) Non Operating Income (2022 - 2026)
Azitra (AZTR) posted Non Operating Income of $6684.0 for Q1 2026, up 375.39% on a QoQ basis from $1406.0 in Q4 2025, and down 79.04% year-over-year from $31893.0 in Q1 2025.
Azitra (AZTR) Non Operating Income (2022 - 2026) Analysis & Trends
Azitra's Non Operating Income history runs 5 years deep, the most recent figure standing at $6684.0 for Q1 2026.
- Quarterly Non Operating Income fell 79.04% year-over-year to $6684.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5595.0 (down 100.28% YoY) and the FY2025 annual result came in at $19614.0, down 99.03% from the prior year.
- Non Operating Income was $6684.0 for Q1 2026 at Azitra, up from $1406.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.9 million in Q3 2024 and bottomed at -$3.0 million in Q2 2023.
- A 5-year average of -$210573.7 and a median of $6684.0 in 2026 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income soared 3705.71% — and 2025, when it plunged 162.36%.
- Azitra's Non Operating Income stood at -$1.3 million in 2022, then soared by 101.8% to $24285.0 in 2023, then surged by 106.11% to $50054.0 in 2024, then tumbled by 97.19% to $1406.0 in 2025, then soared by 375.39% to $6684.0 in 2026.
- Business Quant data shows AZTR's Non Operating Income at $6684.0 in Q1 2026, $1406.0 in Q4 2025, and $3956.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.82 Bn | 1,785.76 Bn | - | - |
| 2 | Akari Therapeutics | 979.03 Bn | 979.03 Bn | - | 444,000.00 |
| 3 | BeOne Medicines | 472.98 Bn | 468.19 Bn | 1.35 Bn | - |
| 4 | Vertex Pharmaceuticals | 123.73 Bn | 116.48 Bn | 2.59 Bn | - |
| 5 | Regeneron Pharmaceuticals | 71.59 Bn | 62.84 Bn | 3.31 Bn | 188.30 Mn |
| 6 | Belite Bio | 62.00 Bn | 62.00 Bn | - | 5.75 Mn |
| 7 | Argenx Se | 54.67 Bn | 49.49 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 37.96 Bn | 34.95 Bn | 959.66 Mn | -46.98 Mn |
| 9 | Revolution Medicines | 36.08 Bn | 36.08 Bn | - | -8.59 Mn |
| 10 | Azitra | 2.07 Mn | 2.07 Mn | - | 6,684.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,684.00 |
| Dec 31, 2025 | 1,406.00 |
| Sep 30, 2025 | 3,956.00 |
| Jun 30, 2025 | -17,641.00 |
| Mar 31, 2025 | 31,893.00 |
| Dec 31, 2024 | 50,054.00 |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 28,287.00 |
| Mar 31, 2024 | 28,622.00 |
| Dec 31, 2023 | 24,285.00 |
| Sep 30, 2023 | 50,443.00 |
| Jun 30, 2023 | -3.00 Mn |
| Mar 31, 2023 | -888,718.00 |
| Dec 31, 2022 | -1.35 Mn |
| Sep 30, 2022 | -47,170.00 |